Medical photo album

Teva Pharmaceuticals has recalled all lots of amlodipine/valsartan combination tablets and amlodipine/valsartan/hydrochlorothiazide combination tablets in the United States after N-nitroso-diethylamine (NDEA) was detected in an active pharmaceutical ingredient (API) manufactured by Mylan India.

NDEA is a probable human carcinogen. The Teva recall, announced November 27, marks the latest recall of tainted sartan products in the United States.

To date, Teva has not received any reports of adverse events related to this recall, the company said.

Detailed information on the recalled product, including lot numbers, expiration dates, strengths, bottle size, and national drug codes are available on the US Food and Drug Administration (FDA) website.

https://www.medscape.com/viewarticle/905630